(Q34900607)

5 August 2017

Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study (English)

1 reference

5 August 2017

0 references

1 reference

Emilio Bouza

3

0 references

Mark H. Wilcox

1

object named as

Mark H Wilcox

0 references

author name string

Kenneth J Tack

2

1 reference

5 August 2017

Daniel L Herr

4

1 reference

5 August 2017

Bernhard R Ruf

5

1 reference

5 August 2017

M Marian Ijzerman

6

1 reference

5 August 2017

Rodney V Croos-Dabrera

7

1 reference

5 August 2017

Mark J Kunkel

8

1 reference

5 August 2017

Charles Knirsch

9

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 January 2009

1 reference

Clinical Infectious Diseases

5 August 2017

1 reference

5 August 2017

48

1 reference

5 August 2017

203-212

1 reference

5 August 2017

2

1 reference

National Healthcare Safety Network (NHSN) Report, data summary for 2006, issued June 2007.

5 August 2017

1 reference

Cost of intensive care unit-acquired bloodstream infections

21 January 2018

1 reference

Clinical and economic outcomes in critically ill patients with nosocomial catheter-related bloodstream infections.

21 January 2018

1 reference

Increased resource use associated with catheter-related bloodstream infection in the surgical intensive care unit

21 January 2018

1 reference

Guidelines for the management of intravascular catheter-related infections

21 January 2018

1 reference

Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens

21 January 2018

1 reference

In vitro activity of linezolid against key gram-positive organisms isolated in the united states: results of the LEADER 2004 surveillance program

21 January 2018

1 reference

Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections

21 January 2018

1 reference

Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections

21 January 2018

1 reference

Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer

21 January 2018

1 reference

Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study

21 January 2018

1 reference

Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia

21 January 2018

1 reference

Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies

21 January 2018

1 reference

Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections

21 January 2018

1 reference

Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials

21 January 2018

1 reference

Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/595686

1 reference

5 August 2017

1 reference